C. Schudt

R. Djukanović, A. Wendel, A. Hatzelmann, 1995, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

Activation of adenylate cyclase and phosphodiesterase inhibition enhance neutral endopeptidase activity in human endothelial cells

E. Fleck, K. Kunkel, K. Graf, 1995, Peptides.

Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation

A. Wendel, F. Gantner, A. Hatzelmann, 1998, British journal of pharmacology.

Phosphodiesterase isozymes modulating inherent tone in human airways: identification and characterization.

H. Magnussen, K. Rabe, G. Dent, 1993, The American journal of physiology.

Attenuation by phosphodiesterase inhibitors of lipopolysaccharide-induced thromboxane release and bronchoconstriction in rat lungs.

S. Uhlig, R. Nüsing, R. Featherstone, 1997, The Journal of pharmacology and experimental therapeutics.

Phosphodiesterase 2 inhibition diminished acute lung injury in murine pneumococcal pneumonia*

N. Suttorp, H. Schütte, B. Schmeck, 2009, Critical care medicine.

Zardaverine and aerosolised iloprost in a model of acute respiratoryfailure

W. Seeger, H. Ghofrani, N. Weissmann, 2003, European Respiratory Journal.

Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity.

W. Seeger, H. Ghofrani, N. Weissmann, 2001, American journal of respiratory and critical care medicine.

Therapeutic potential of selective PDE inhibitors in asthma.

F. Gantner, A. Hatzelmann, C. Schudt, 1999, Pulmonary pharmacology & therapeutics.

Cyclic nucleotide phosphodiesterases from purified human CD4+ and CD8+ T lymphocytes

R. Djukanović, A. Wendel, A. Hatzelmann, 1995, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

Hyperpermeability of pulmonary endothelial monolayer: Protective role of phosphodiesterase isoenzymes 3 and 4

N. Suttorp, S. Hippenstiel, M. Krüll, 2004, Lung.

Effects of selective and non-selective phosphodiesterase inhibitors on tracheal mucus secretion in the rat.

P. von Wichert, C. Schudt, D. Bredenbröker, 1996, European journal of pharmacology.

Physical properties of muscle cell membranes during fusion. A fluorescence polarization study with the ionophore A23187.

D. Brdiczka, E. Weidekamm, C. Schudt, 1976, Biochimica et biophysica acta.

Cyclic nucleotide phosphodiesterase in human bronchial epithelial cells: characterization of isoenzymes and functional effects of PDE inhibitors.

H. Magnussen, K. Rabe, G. Dent, 1998, Pulmonary pharmacology & therapeutics.

pathway of primary mouse CD3+ T lymphocytes and PKA are antagonistic partners in the NF-AT transactivation θ PKC

G. Baier, M. Leitges, A. Hatzelmann, 2013 .

PKCtheta and PKA are antagonistic partners in the NF-AT transactivation pathway of primary mouse CD3+ T lymphocytes.

G. Baier, M. Leitges, A. Hatzelmann, 2006, Blood.

Cellular recognition by rat liver cells of neuraminidase-treated erythrocytes. Demonstration and analysis of cell contacts.

H. Kolb, C. Schudt, V. Kolb‐Bachofen, 1978, Experimental cell research.

Fusion of isolated myoblast plasma membranes. An approach to the mechanism.

M. Gratzl, G. Dahl, C. Schudt, 1978, Biochimica et biophysica acta.

Influence of the ionophore A 23 187 on myogenic cell fusion

D. Pette, C. Schudt, 1975, FEBS letters.

The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages.

F. Schade, C. Schudt, Schade Fu, 1993, European journal of pharmacology.

Phosphodiesterase isoenzyme families in human osteoarthritis chondrocytes – functional importance of phosphodiesterase 4

E. Hedbom, A. Hatzelmann, H. Häuselmann, 2002, British journal of pharmacology.

Protection by phosphodiesterase inhibitors against endotoxin-induced liver injury in galactosamine-sensitized mice.

A. Wendel, C. Schudt, W. Fischer, 1993, Biochemical pharmacology.

Inhibition of IgE-mediated histamine release from human peripheral leukocytes by selective phosphodiesterase inhibitors.

W. Schunack, J. Kleine‐Tebbe, C. Schudt, 1992, Agents and actions.

Ca2+ -ions as coupling agents in enzymatic differentiation and carbohydrate metabolism of cultured muscle cells.

D. Pette, C. Schudt, 1977, Advances in enzyme regulation.

D. Pette, G. Dölken, C. Schudt, 1975, European journal of biochemistry.

The existence of stable enantiomers of telenzepine and their stereoselective interaction with muscarinic receptor subtypes.

N. Birdsall, E. Hulme, C. Schudt, 1989, Molecular pharmacology.

Cryofixation of monolayer cell cultures for freeze‐fracturing without chemical pre‐treatments

H. Plattner, C. Schudt, P. Pscheid, 1981, Journal of microscopy.

Identification of phosphodiesterase IV activity and its cyclic adenosine monophosphate-dependent up-regulation in a human keratinocyte cell line (HaCaT).

A. Wendel, A. Hatzelmann, C. Schudt, 1995, The Journal of investigative dermatology.

Influence of selective phosphodiesterase inhibitors on human neutrophil functions and levels of cAMP and Cai

V. Ullrich, C. Schudt, S. Winder, 1991, Naunyn-Schmiedeberg's Archives of Pharmacology.

Inhibition of muscle cell fusion in vitro by Mg2+ and K+ ions

D. Pette, C. Schudt, J. van der Bosch, 1973, FEBS letters.

Pharmacological evidence for selective inhibition of gastric acid secretion by telenzepine, a new antimuscarinic drug.

W. Simon, C. Schudt, M. Eltze, 1985, European journal of pharmacology.

Specificity of the substituted benzimidazole B 823-08: a prodrug for gastric proton pump inhibition.

C. Schudt, K. Heintze, M. Eltze, 1987, Pharmacology.

Regulation of phosphoenolpyruvate carboxykinase by glucagon and glucocorticoids in primary cultures of rat hepatocytes.

C. Schudt, 1980, Biochimica et biophysica acta.

2 – Analysis of PDE Isoenzyme Profiles in Cells and Tissues by Pharmacological Methods

C. Schudt, H. Tenor, 1996 .

Pharmacological characterization of muscarine receptors of PC 12 (rat phaeochromocytoma) cells

H. Bönisch, R. Boer, C. Schudt, 1990, Naunyn-Schmiedeberg's Archives of Pharmacology.

Phosphodiesterase inhibitors: history of pharmacology.

A. Hatzelmann, C. Schudt, H. Tenor, 2011, Handbook of experimental pharmacology.

The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.

A. Hatzelmann, S. Adnot, G. Lungarella, 2010, Pulmonary pharmacology & therapeutics.

Effect of portacaval anastomosis on hepatic HMG‐CoA‐reductase activity in normal rats

C. Schudt, F. Ossenberg, U. Gaertner, 1977, FEBS letters.

The sulphoxide moiety of substituted benzimidazoles is essential for inhibition of parietal cell K+/H+‐ATPase

K. Sewing, W. Beil, C. Schudt, 1986, British journal of pharmacology.

Phosphodiesterase 1 Upregulation in Pulmonary Arterial Hypertension: Target for Reverse-Remodeling Therapy

W. Seeger, S. Pullamsetti, H. Ghofrani, 2007, Circulation.

Roflumilast inhibits leukocyte‐endothelial cell interactions, expression of adhesion molecules and microvascular permeability

J. Klar, A. Hatzelmann, J. Cortijo, 2007, British journal of pharmacology.

The binding of a K+ competitive ligand, 2-methyl,8-(phenylmethoxy)imidazo(1,2-a)pyridine 3-acetonitrile, to the gastric (H+ + K+)-ATPase.

D. Keeling, A. Taylor, C. Schudt, 1989, The Journal of biological chemistry.

Adenosine receptor-blocking xanthines as inhibitors of phosphodiesterase isozymes.

G. Sybrecht, D. Ukena, C. Schudt, 1993, Biochemical pharmacology.

Smokers with COPD Show a Shift in Energy and Nitrogen Metabolism at Rest and During Exercise

D. DeLuca, T. Illig, J. Hohlfeld, 2020, International journal of chronic obstructive pulmonary disease.

COPD_A_217474 1..13

D. DeLuca, T. Illig, J. Hohlfeld, 2020 .

Calcium induced fusion of plasma membranes isolated from myoblasts grown in culture

M. Gratzl, G. Dahl, C. Schudt, 1976 .

Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: a comparative study.

A. Wendel, F. Gantner, A. Hatzelmann, 1997, The Journal of allergy and clinical immunology.

Effect of nitric oxide synthase (NOS) inhibition on macro- and microcirculation in a model of rat endotoxic shock

W. Seeger, B. Rosengarten, S. Pullamsetti, 2006, Thrombosis and Haemostasis.

Is phosphodiesterase inhibition a relevant bronchospasmolytic principle?

C. Schudt, M. Eltze, R. Beume, 1989, Agents and actions. Supplements.

Actions of the phosphodiesterase inhibitor zardaverine on guinea-pig ventricular muscle

M. Galvan, C. Schudt, 1990, Naunyn-Schmiedeberg's Archives of Pharmacology.

The binding of [3H]telenzepine to muscarinic acetylcholine receptors in calf forebrain.

N. Birdsall, C. Schudt, C. Auriga, 1988, European journal of pharmacology.

Interaction of telenzepine with muscarinic receptors in mammalian sympathetic ganglia.

M. Galvan, R. Boer, C. Schudt, 1989, European journal of pharmacology.

A Serine Protease-Dependent Mechanism of Apoptosis after Caspase Arrest

C. Schudt, 2004 .

(+)-Niguldipine binds with very high affinity to Ca2+ channels and to a subtype of alpha 1-adrenoceptors.

H. Glossmann, A. Grassegger, R. Boer, 1989, European journal of pharmacology.

Role of phosphodiesterases in the regulation of endothelial permeability in vitro.

T. Welsch, C. Schudt, U. Weber, 1993, The Journal of clinical investigation.

Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.

A. Hatzelmann, C. Schudt, 2001, The Journal of pharmacology and experimental therapeutics.

Regulation of glycogen synthase interconversion in cultured muscle cells: Actions of insulin, calcium, ionophore A 23187 and cytochalasin B

D. Pette, C. Schudt, U. Gaertner, 1977, Molecular and Cellular Endocrinology.